Skip to main content Skip to main navigation menu Skip to site footer

The association between p53 and FGFR3 expression with the aggressiveness of bladder invasive urothelial carcinoma cases in Prof. dr. IGNG Ngoerah Hospital, Bali, Indonesia

  • Ni Wayan Winarti ,
  • I Wayan Juli Sumadi ,
  • Luh Putu Iin Indrayani Maker ,
  • Elisabeth Ernawaty Ndori ,
  • Elisa Laura Oktrinita Sitohang ,

Abstract

Background: Bladder urothelial carcinoma (BUC) shows varying histological features, behavior, and prognosis. The two most common genes altered in BUC were TP53 and FGFR3. The FGFR3 alteration related to lesser aggressiveness than TP53 and anti-FGFR3 targeted therapy is being investigated. This study determined p53 and FGFR3 expression in BUC cases treated at Prof. dr. IGNG Ngoerah Hospital.

Methods: A cross-sectional observational analytic study was conducted in 2023 in the Anatomical Pathology Laboratory at Prof. dr. IGNG Ngoerah Hospital. The subjects were forty-three BUC patients from 2018-2022 who met the eligibility criteria obtained by consecutive sampling. Tumor aggressiveness, represented by the degree of differentiation and depth of invasion, was assessed from HE slides, resulting in low and high-grade muscle-invasive (MI) and non-muscle-invasive (NMI) cases. The p53 and FGFR3 expression were assessed with immunostaining and categorized as low and high expression with 50% and 70% cut-off of positive cells, respectively. The association between variables was statistically analyzed with the Fisher Exact test.

Results: Most patients were male (82.44%), aged >50 years (92.37%), invasive type (62.60%), high grade (80.12%), and MI (52.67%). Immunostaining showed a predominance of high p53 expression (60.5%) and low FGFR3 expression (62.8%). Some cases showed concomitant p53 and FGFR3 expression. Statistical analysis revealed no association between p53 expression and the degree of differentiation and depth of invasion (p=0.625; 0.388, respectively). There was a significant association between FGFR3 expression and the degree of differentiation (p=0.003) but not with the depth of invasion (p=0.110).

Conclusion: In conclusion, p53 expression was not associated with BUC aggressiveness, whereas FGFR3 expression was significantly associated with the degree of differentiation but not with the depth of invasion. Concomitant p53 and FGFR3 expression may reflect the complexity of BUC carcinogenesis. Further studies are needed for a better understanding of TP53 and FGFR3's involvement in BUC carcinogenesis and therapy.

Section

References

  1. Comperal EM, Netto GJ, Tsuzuki T. Tumours of the Urinary Tract. In: Amin MB, Berney DM, Comperal EM, Hartmann A, Menon S, Netto GJ, et al. Urinary and Male Genital Tumours. Lyon(France): I.A.R.C. 2022;1(1)131-150.
  2. Zhu S, Yu W, Yang X, Wu C, & Cheng F. Traditional Classification and Novel Subtyping Systems for Bladder Cancer. Frontiers in Oncology. 2020;10(102):1–13.
  3. Apolo AB, Vogelzang NJ, & Theodorescu D. New and Promising Strategies in the Management of Bladder Cancer. ASCO Educational Book. 2015;1(1):105–112.
  4. Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology. 2020;77(4):420–433.
  5. Li Y, Sun L, Guo X, Mo N, Zhang J, & Li C. Frontiers in Bladder Cancer Genomic Research. Frontiers in Oncology. 2021;11(5):1–10.
  6. Kim YS, Kim K, Kwon GY, Lee SJ, & Park SH. Fibroblast Growth Factor Receptor 3 (FGFR3) Aberrations in Muscle-invasive Urothelial Carcinoma. BMC Urology. 2018;18(1):1–7.
  7. Joyce C, Rayi A, & Kasi A. Tumor-suppressor genes. StatPearls. 2022. Accessed on: 11th November 2023 https://www.ncbi.nlm.nih.gov/books/NBK532243/
  8. The Global Cancer Observatory. Cancer Incident in Indonesia. International Agency for Research on Cancer. 2020;1(858):p1–2.
  9. Hodgson A, Xu B, Downes MR. p53 Immunohistochemistry in High-grade Urothelial Carcinoma of the Bladder is Prognostically Significant. Histopathology 2017;71(2),296–304.
  10. Jamidi SK. Perbedaan Imunoekspresi Fibroblast Growth Factor Receptor-3 (FGFR3) pada Karsinoma Urotelial Kandung Kemih Derajat Rendah dan Derajat Tinggi, serta Hubungannya dengan Stadium Tumor. Program Studi Ilmu Patologi Anatomik FK UI. 2018. [Accessed on: 20th November 2023] [Available at: https://perpustakaan.fk.ui.ac.id/new-opac/index.php?p=show_detail&id=24078].
  11. Winarti NW, Widayanti LA. Clinicopathological Profile of Patients with Bladder Lesions in Sanglah Hospital during the Period 2013-2017. Gaceta Medica de Caracas. 2022;130(Supl 1):S73–S78.
  12. Raspollini MR, Comperat EM, Lopez-Beltran A, Montironi R, Cimadamore A, Tsuzuki T, & Netto GJ. News in the classification of WHO 2022 bladder tumors. Pathologica. 2023;1(1):1–9.
  13. Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. Bladder Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Annals of Oncology. 2022;33(3):244–258.
  14. Lyu Q, Lin A, Cao M, Xu A, Luo P, & Zhang J. Alterations in TP53 are a Potential Biomarker of Bladder Cancer Patients who Benefit from Immune Checkpoint Inhibition. Cancer Control. 2020;27(1):1–15.
  15. Liao Y, Tang H, Wang M, Wang K, Wang Y, Jiang N. The Potential Diagnosis Role of TP53 Mutation in Advanced Bladder Cancer: A Meta-analysis. Journal of Clinical Laboratory Analysis. 2021;35(5),]:1–7.
  16. Wu G, Wang F, Li K, Li S, Zhao C, Fan C, & Wang J. Significance of TP53 Mutation in Bladder Cancer Disease Progression and Drug Selection. PeerJ. 2019;1(12):1-9.
  17. Kacew A, Sweis RF FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer. In Frontiers in Immunology. 2020;11(1):1-10.
  18. Wiranata S, Anjani IAW, Saputra IPGS, Sadvika IGAS, Prabawa IPY, Supadmanaba IG, et al. Pretreatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as a stage determination in breast cancer. Open Access Macedonian Journal of Medical Sciences. 2020;8(B):1058-1063.
  19. Salsabila S, Lazuardi MAS, Rosandy KO. Management of urethral stricture due to prostate cancer and colorectal cancer radiotherapy: a systematic review. Bali Medical Journal. 2019;8(3):788–792.
  20. Duarsa G.W.K., Pratama PKD, Sabudi IMNG, Oktavius D. Graft procedure on urethroplasty, in comparison with flap procedure: a literature review. Bali Medical Journal. 2019;8(3):772–775.
  21. Yusuf M, Yogiswara N, Setiawan MR, Salsabila S, Soebadi MA, Wirjopranoto S. Preoperative alpha-blockers to facilitate ureteral access sheath (UAS) insertion: a systematic review and meta-analysis. Bali Medical Journal. 2023;12(1):291–298.

How to Cite

Winarti, N. W., Sumadi, I. W. J., Maker, L. P. I. I., Ndori, E. E., & Sitohang, E. L. O. (2024). The association between p53 and FGFR3 expression with the aggressiveness of bladder invasive urothelial carcinoma cases in Prof. dr. IGNG Ngoerah Hospital, Bali, Indonesia. Indonesia Journal of Biomedical Science, 18(1), 77–82. https://doi.org/10.15562/ijbs.v18i1.536

HTML
25

Total
39

Share

Search Panel

Ni Wayan Winarti
Google Scholar
Pubmed
IJBS Journal


I Wayan Juli Sumadi
Google Scholar
Pubmed
IJBS Journal


Luh Putu Iin Indrayani Maker
Google Scholar
Pubmed
IJBS Journal


Elisabeth Ernawaty Ndori
Google Scholar
Pubmed
IJBS Journal


Elisa Laura Oktrinita Sitohang
Google Scholar
Pubmed
IJBS Journal